vivi
Lv71
4180 积分
2022-09-16 加入
-
Gout in China, 1990-2017: the Global Burden of Disease Study 2017
4小时前
已完结
-
A Phase 3 prospective, multi-center, double-blind, randomized trial of saroglitazar 4 mg compared to placebo in patients with non-alcoholic steatohepatitis
25天前
已关闭
-
Low acid uric in primary prophylaxis: worthy?
25天前
已完结
-
Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
26天前
已完结
-
Evaluating the drug-drug interactions of SHR4640 on repaglinide and midazolam in healthy subjects
1个月前
已完结
-
Liraglutide and Liver Injury: Rare Case Report with Literature Review
1个月前
已完结
-
A very rare cause of markedly elevated CA 19–9: Glucagon-like peptide-1 receptor agonists
1个月前
已完结
-
2016中国痛风诊疗指南
1个月前
已完结
-
2016中国痛风诊疗指南
1个月前
已关闭
-
Effect of Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of SHR4640, a Selective Human Urate Transporter 1 Inhibitor
1个月前
已完结